GlassScriptPhysician profile
Harsh D Patel
NPI 1598159733
$13,371.24
in general payments reported to CMS, 2019-2025
45 companies · $4,276 in 2025
The $4,276 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,657 · 2020: $296 · 2021: $388 · 2022: $1,012 · 2023: $1,304 · 2024: $4,438 · 2025: $4,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,578 · Travel and Lodging: $1,424 · Education: $16.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,577.81 |
| Travel and Lodging | $1,424.10 |
| Education | $16.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,725.45 | 2019-2025 | |
| Abbott Laboratories | $2,399.86 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Advisor |
| Janssen Biotech, INC. | $1,388.37 | 2019-2025 | Tremfya, Stelara |
| Medtronic Vascular, INC. | $843.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $726.98 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $593.14 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $525.49 | 2024-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $460.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $422.52 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $402.85 | 2023-2025 | Voquezna |
| Genzyme Corporation | $337.12 | 2022-2025 | |
| Qol Medical, LLC | $316.05 | 2023-2025 | Sucraid, Sucraid |
| Pfizer INC. | $218.93 | 2023-2025 | |
| Intercept Pharmaceuticals, INC. | $197.34 | 2021-2024 | |
| Lilly USA, LLC | $187.71 | 2024-2025 | Omvoh |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,285.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.